Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature.

[1]  J. Lehmann.  Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effect of tryptophan on mental disturbances. , 2009, Acta medica Scandinavica.

[2]  G. Burg,et al.  Levodopa und malignes Melanom – Fallbericht und Literaturübersicht Ein Beitrag zur Frage des Kausalzusammenhanges zwischen Levodopa und der Entwicklung eines malignen Melanoms , 1996, Der Hautarzt.

[3]  P. Schmid‐Grendelmeier,et al.  [Levodopa and malignant melanoma--case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma]. , 1996, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[4]  W. Lambert,et al.  The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. , 1994, Archives of dermatology.

[5]  H. Fiedler,et al.  Zur diagnostischen Bedeutung des α-MSH beim malignen Melanom des Menschen , 1994, Der Hautarzt.

[6]  S. Tyring,et al.  NONSUNLIGHT RISK FACTORS FOR MALIGNANT MELANOMA PART II: IMMUNITY, GENETICS, AND WORKPLACE PREVENTION , 1994, International journal of dermatology.

[7]  G. Schwartze,et al.  [The diagnostic significance of alpha-MSH in malignant melanoma of man]. , 1994, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[8]  S. Tyring,et al.  NONSUNLIGHT RISK FACTORS FOR MALIGNANT MELANOMA PART I: CHEMICAL AGENTS, PHYSICAL CONDITIONS, AND OCCUPATION , 1994, International journal of dermatology.

[9]  F. Trautinger,et al.  Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. , 1994, The Journal of clinical investigation.

[10]  P. Hersey,et al.  An analysis of a melanoma epidemic , 1993, International journal of cancer.

[11]  W. Weiner,et al.  Levodopa, melanoma, and Parkinson's disease , 1993, Neurology.

[12]  I. Lundberg,et al.  Mortality and cancer incidence among PVC-processing workers in Sweden. , 1993, American journal of industrial medicine.

[13]  S. Rosso,et al.  Cutaneous melanoma and sunburns in childhood in a southern European population. , 1992, European journal of cancer.

[14]  A. Slominski,et al.  Dopa inhibits induced proliferative activity of murine and human lymphocytes. , 1992, Anticancer research.

[15]  V. Thaller,et al.  Lid melanoma and parkinsonism. , 1992, The British journal of ophthalmology.

[16]  R. Sandyk.  Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland. , 1992, The International journal of neuroscience.

[17]  M. Merello,et al.  Impaired levodopa response in Parkinson's disease during melanoma therapy. , 1992, Clinical neuropharmacology.

[18]  M. Kripke.  Immunological Effects of Ultraviolet Radiation , 1991, The Journal of dermatology.

[19]  C. Garbe,et al.  Incidence and mortality of malignant melanoma in Berlin (West) from 1980 to 1986. , 1991, Acta dermato-venereologica.

[20]  P. Jastreboff,et al.  L-Tyrosine stimulates induction of tyrosinase activity by MSH and reduces cooperative interactions between MSH receptors in hamster melanoma cells , 1989, Bioscience reports.

[21]  M. Wick.  Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells. , 1989, The Journal of investigative dermatology.

[22]  D. Elder.  Human melanocytic neoplasms and their etiologic relationship with sunlight. , 1989, The Journal of investigative dermatology.

[23]  P. M. Ross,et al.  Actinic DNA damage and the pathogenesis of cutaneous malignant melanoma. , 1989, The Journal of investigative dermatology.

[24]  J. Bystryn.  Immunosurveillance and melanoma. , 1989, The Journal of investigative dermatology.

[25]  D. Schachtschabel,et al.  Augmentation by L-dopa of growth inhibition and melanin formation of X-irradiated Harding-Passey melanoma cells in culture. , 1988, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[26]  T. A. Amer,et al.  Effect of L-dopa on the growth of human melanoma cells in vitro. , 1987, Journal de pharmacie de Belgique.

[27]  M. Maggini,et al.  A hypothesis on the etiology of malignant melanoma: the role of chemicals interfering with melanin synthesis. , 1987, European journal of cancer & clinical oncology.

[28]  J. Pawelek,et al.  Phosphorylated isomers of L-dopa stimulate MSH binding capacity and responsiveness to MSH in cultured melanoma cells. , 1987, Biochemical and biophysical research communications.

[29]  M. Wick.  Inhibition of transformation by levodopa-carbidopa in lymphocytes derived from patients with melanoma. , 1987, The Journal of investigative dermatology.

[30]  F. Marks,et al.  Experimental evidence that skin carcinogenesis is a multistep phenomenon , 1986, The British journal of dermatology.

[31]  G. Ghanem,et al.  Increased serum alpha-melanocyte stimulating hormone (alpha-MSH) in human malignant melanoma. , 1986, European journal of cancer & clinical oncology.

[32]  M. Landthaler,et al.  Development of two malignant melanomas during administration of levodopa. , 1985, Acta dermato-venereologica.

[33]  A. Kochar.  Development of malignant melanoma after levodopa therapy for Parkinson's disease. Report of a case and review of the literature. , 1985, The American journal of medicine.

[34]  F. Rampen,et al.  Levodopa and melanoma: three cases and review of literature. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[35]  J. Jankovic,et al.  Low cancer rates among patients with Parkinson's disease , 1985, Annals of neurology.

[36]  D. Abramson,et al.  Choroidal melanoma and levodopa. , 1984, JAMA.

[37]  M. Rosin,et al.  Malignant melanoma and levodopa. , 1984, Cutis.

[38]  M. Wick.  The chemotherapy of malignant melanoma. , 1983, The Journal of investigative dermatology.

[39]  P T De Jong,et al.  Uveal malignant melanoma and levodopa therapy in Parkinson's disease. , 1982, Ophthalmology.

[40]  L. Morrison,et al.  DNA damage and selective toxicity of dopa and ascorbate:copper in human melanoma cells. , 1982, Cancer research.

[41]  Pawelek Jm,et al.  The biosynthesis of mammalian melanin. , 1982 .

[42]  W. Clark,et al.  MALIGNANT MELANOMA IN RENAL-TRANSPLANT RECIPIENTS , 1981, The Lancet.

[43]  K. Soltani,et al.  Levodopa administration and multiple primary cutaneous melanomas. , 1980, Archives of dermatology.

[44]  M. Wick.  An experimental approach to the chemotherapy of melanoma. , 1980, The Journal of investigative dermatology.

[45]  M. Wick,et al.  Levodopa and Melanoma-Reply , 1979 .

[46]  P. Nordström,et al.  [Connection between levodopa therapy and malignant tumors]. , 1979, Lakartidningen.

[47]  M. Wick,et al.  Levodopa therapy and malignant melanoma. , 1978, JAMA.

[48]  M. Wick,et al.  Enhancement of L-dopa incorporation into melanoma by dopa decarboxylase inhibition. , 1978, The Journal of investigative dermatology.

[49]  K. Nishioka,et al.  Tyrosinase activity in the sera of patients with malignant melanoma: Method and specificity , 1977, International journal of cancer.

[50]  M. Wick,et al.  Selective incorporation of L-3,4-dihydroxyphenylalanine by S-91 Cloudman melanoma in vitro. , 1977, Cancer research.

[51]  J. Shupack,et al.  Levodopa and melanoma , 1974, Neurology.

[52]  B. Hirshowitz,et al.  Exposure to asbestos and the genesis of pleural plaques and neoplasia. , 1973 .

[53]  M. Netsky,et al.  Prevalence of neoplasms and causes of death in paralysis agitans A necropsy study , 1973, Neurology.

[54]  E. Gilbert,et al.  Multiple primary melanoma following administration of levodopa. , 1972, Archives of pathology.

[55]  H. Käser,et al.  Quantitative fluorimetric determination of urinary dopa and its significance for the diagnosis of neural crest tumours. , 1971, Clinica chimica acta; international journal of clinical chemistry.

[56]  H. Lebovitz,et al.  Stimulation of human-growth-hormone secretion by L-dopa. , 1970, The New England journal of medicine.

[57]  O. Hornykiewicz.  Dopamine (3-hydroxytyramine) and brain function. , 1966, Pharmacological reviews.

[58]  H. Demopoulos,et al.  Effects of reducing the phenylalanine‐Tyrosine intake of patients with advanced malignant melanoma , 1966, Cancer.

[59]  M. Shimkin,et al.  Further studies on the effects of pituitary growth hormone (STH) on C3H mice bearing a transplanted mammary adenocarcinoma. , 1954, Cancer research.

[60]  C. Huber,et al.  Melanom-Induktion durch chemische Substanzen? ein Literaturüberblick , 1995 .

[61]  O. Axelson,et al.  Radon as a risk factor for extra-pulmonary tumours , 1993, Medical oncology and tumor pharmacotherapy.

[62]  L. Goldsmith.  Physiology, biochemistry, and molecular biology of the skin , 1991 .

[63]  R. Kefford,et al.  The use of L-dopa and carbidopa in metastatic malignant melanoma. , 1991, The Journal of investigative dermatology.

[64]  R. Sandyk.  Pineal melatonin functions: possible relevance to Parkinson's disease. , 1990, The International journal of neuroscience.

[65]  M. Kutner,et al.  Plasma L-dopa in the diagnosis of malignant melanoma. , 1986, Clinical chemistry.

[66]  A. Marchionini.  Fortschritte der Praktischen Dermatologie und Venerologie , 1952 .